Clinical Trial Search

Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months

Primary: Number of Participants With Treatment Success From Day 10 to Day 13 — 12; 9; 19; 13 Participants

Primary: Percent Change in Liver Volume — -5.0; 0.9 percent change — p=0.048

Primary: Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24) — -1.7; -2.1 µg/L

Primary: Percentage of Participants Developing Diarrhea (Grade 1 to 4) — 76.1; 78.9 Percentage of Participants

Primary: Percentage of Responders at the End of the Core Treatment Period — 86.9; 66.7; 40.4; 64.9 Percentage of responders

Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants

Primary: Median Time to Paracentesis — 28; 14 days — p=0.17

Primary: Proportion of Patients Who Are Biochemically Controlled Throughout the RCT Phase — 50; 37 Participants

Primary: Percentage of Days With Subcutaneous Octreotide as Rescue Medication — 33.72; 48.49 Percentage of days — p=0.0165

Primary: Compared Colonic Motility Index From Fasting to Post Octreotide Infusion — 6.03; 6.89; 7.73; 5.32 mm Hg — p=0.087

Primary: Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill — 371.52; 392; 4767; 5159 minutes — p=0.07

Primary: Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC — 6.23; 24.1…

Primary: Percentage of Patients Who Achieved Clinical Symptom Improvement by Randomization Stratum and Treatment. — 13.5; 28.2; 100; 20.0 Percentage of Participants

Primary: Bronchial Secretion Volume Over Preceding 24 Hour Period — 220; 310; 200; 70 mL/24 hr

Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…

Primary: Plasma Octreotide Level After Each Treatment Phase — 885; 1167 pg/mL — p=0.40

Primary: Mean Pain Scores at 3 Months — 2.4; 2.4; 1.9; 1.9 scores on a scale

Primary: To Measure Safety of 68Ga-DOTATOC Positron Emission Tomography (PET) by Measuring the Number of Adverse Events Related to the Investigational Radiopharmaceutical Agent…

Primary: Participants With Trough Human Growth Hormone < 2.5 ug/mL — 1; 8; 4; 6 participants with trough hGH < 2.5 µg/mL

Primary: Number of Participants With Side-Effects — 10 participants

Primary: Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1. — 15.4; 20.0; 0 percentage of participants…

Primary: Progression Free Survival (PFS) — NA; 8.5 months — p=<0.0001

Primary: IGF-1 Level on Sandostatin LAR — 336; 186; 487 ng/mL — p=<0.05

Primary: Percentage of Responders Before or at Day 7 — 88.2; 25.7; 46.2 percentage of responders — p=0.0055

Primary: Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days) — 44.4; 55.6 Percentage of…

Primary: Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1 — 31.3; 19.2; 39.4; 21.8 Percentage of Participants — p=0.007

Primary: Disease Control Rate (DCR) Assessed Locally at Month 9 — 35.0; 45.2; 45.0 percentage of participants — p=0.2968

Primary: Progression-Free Survival (PFS) — NA; 72 Weeks — p=<0.001

Primary: Four-month Progression-free Survival Rate — 78.5 percentage of participants — p=<0.001